SCHEMBL4479696

SCHEMBL4479696

N=C(N)Nc1nc2ccc(Cl)cc2[nH]1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 1/20 0.54
RAB9A P51151 4/20 0.54
CYP1A2 P05177 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
HTR3E A5X5Y0 1/20 0.53
HTR3B O95264 1/20 0.53
HTR3A P46098 1/20 0.53
BACE1 P56817 1/20 0.53
HTR3D Q70Z44 1/20 0.53
HTR3C Q8WXA8 1/20 0.53
F10 P00742 1/20 0.52
RIPK1 Q13546 1/20 0.51
POLB P06746 1/20 0.51
LPAR2 Q9HBW0 1/20 0.50
IRAK4 Q9NWZ3 1/20 0.49
KLK1 P06870 1/20 0.49
KLK5 Q9Y337 1/20 0.49
PSMB8 P28062 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5924163 0.88 RAB9A (0.45) HRH4RAB9ACYP1A2CYP2D6CYP2C9
Hydrochloric Acid SCHEMBL11786459 0.87 RAB9A (0.44) HRH4RAB9ACYP1A2CYP2D6CYP2C9
SCHEMBL29609514 0.82 TUBB4A (0.58) RAB9ACYP1A2F10POLBIRAK4
SCHEMBL3833609 0.81 F10 (0.47) F10
SCHEMBL21855856 0.79 HTR3E (0.61) HRH4RAB9ACYP1A2CYP2D6CYP2C9
SCHEMBL29610185 0.78 ALDH1A1 (0.60) RAB9AF10POLBIRAK4KLK1
SCHEMBL11706161 0.78 NPC1 (0.72) HRH4RAB9APOLBLPAR2IRAK4
SCHEMBL707871 0.78 CYP3A4 (0.71) RAB9APOLBTDP1ALDH1A1SMN1; SMN2
SCHEMBL11171725 0.77 LMNA (0.63) HRH4CYP1A2CYP2D6CYP2C9CYP2C19
Hydrochloric Acid SCHEMBL7080808 0.76 CYP3A4 (0.69) RAB9APOLBTDP1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582630-B2 Pyradazine compounds as GSK-3 inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-09-01 US disclosed
US-7279473-B2 Pyrazolopyridazine derivatives SMITHKLINE BEECHAM CORPORATION (US) 2007-10-09 US disclosed
EP-1463730-B1 PYRAZOLOPYRIDAZINE DERIVATIVES SMITHKLINE BEECHAM CORP (US) 2006-04-19 EP disclosed
US-20060069097-A1 Pyradazine compounds as gsk-3 inhibitors SMITHKLINE BEECHAM CORPORATION 2006-03-30 US disclosed
EP-1551842-A1 PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-07-13 EP disclosed
US-20050090507-A1 Pyrazolopyridazine derivatves SMITHKLINE BEECHAM CORPORATION 2005-04-28 US disclosed
WO-2004035588-A1 PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090507-A1 Pyrazolopyridazine derivatves CDK4, CDK3, CDK8 HRH4 2056/4885RAB9A 2004/4885CYP1A2 1820/4885
US-20060069097-A1 Pyradazine compounds as gsk-3 inhibitors GSK3B, GSK3A, GSKIP HRH4 3442/4885RAB9A 2488/4885CYP1A2 1986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.